Rabbit Her2/ErbB2 Protein

<strong>Rabbit Her2/ErbB2 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2014835_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 71 kDa_x000D_ <strong>Supplied as:</strong> Lyophilized_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules Bioconjug Chem. 2008 Jan;19(1):235-43._x000D_ 2: Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine J Nucl Med. 2009 May;50(5):781-9._x000D_ 3: Lindberg H, Hofström C, Altai M, Honorvar H, Wållberg H, Orlova A, Ståhl S, Gräslund T, Tolmachev V. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus Tumour Biol. 2012 Jun;33(3):641-51._x000D_ 4: Sommaruga S, Lombardi A, Salvadè A, Mazzucchelli S, Corsi F, Galeffi P, Tortora P, Prosperi D. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells Appl Microbiol Biotechnol. 2011 Aug;91(3):613-21._x000D_ 5: D'Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, De Raeve H, Muyldermans S, Caveliers V, Devoogdt N, Lahoutte T. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody Theranostics. 2014 Apr 25;4(7):708-20._x000D_ 6: Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I J Med Chem. 2011 Jun 9;54(11):3817-26._x000D_ 7: Schlapschy M, Theobald I, Mack H, Schottelius M, Wester HJ, Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life Protein Eng Des Sel. 2007 Jun;20(6):273-84._x000D_ 8: Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Cancer Cell. 2021 Jul 12;39(7):989-998.e5._x000D_ 9: Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet. 2017 Mar 25;389(10075):1195-1205._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/35439025">10: Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update J Clin Oncol. 2022 Jun 1;40(16):1816-1837. </a>_x000D_ _x000D_ <strong>Products Related to Rabbit Her2/ErbB2 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>